Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of SEP-226330 in Restless Legs Syndrome
2004-003661-33Phase 2Completed
- Sponsor
- Sunovion
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in restless legs syndrome (RLS) comparing SEP-226330 with Placebo (2 arms). Primary endpoint: Change in IRLSSG score from baseline to end of treatment. Started Dec 2004; status: completed.
02
Drugs
SEP-226330
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2004-003661-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003661-33.